Transaction · 0001635088-26-000015

Sukhatme Mayukh

Sukhatme Mayukh, PRES, CIO, reported a transaction classified as exercise at Roivant Sciences Ltd. involving 651558.000000 shares for an estimated $0.00. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

exerciseSEC transaction code MPRES, CIO
ROIVRoivant Sciences Ltd.
Filing timeFeb 11
Trade dateFeb 09, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$26.80
Pre-filing
1mo ago -18.0%1w ago -18.1%1d ago -3.7%
Returns since
7d +2.5%30d +4.7%90d +9.7%180d +33.5%1y +36.5%

ROIV price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ROIV since 2026-02-11Filed 205 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
exercise
Code M
Identifier
0001635088-26-000015
Stock Option (Right to Buy)
Transaction date
Feb 09, 2026
Filed Feb 11, 2026, 10:53 PM · 2d delay
Shares
651k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
0 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President & CIO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide…

  2. F2

    These Common Shares were sold in multiple transactions at prices ranging from $25.92 to $26.78, inclusive.

  3. F3

    Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.

  4. F4

    Award of stock options to purchase Common Shares that is fully vested.

Original filing · 0001635088-26-000015
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ROIV